News: news

GPN Vaccines raises AUD$1.1 million

GPN Vaccines

GPN Vaccines, a vaccine development company focussed on the prevention of diseases caused by the world’s foremost bacterial pathogen, Streptococcus pneumoniae, has raised AUD$1.1 million (USD$0.8 million) towards development of its proprietary vaccine, Gamma-PNTM.

[Read more about GPN Vaccines raises AUD$1.1 million]

New blood test detects early stage Ovarian Cancer

Research on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer - a disease which kills over 1000 Australian women and 150,000 globally each year.

[Read more about New blood test detects early stage Ovarian Cancer]

SA’s innovative 3D printers boosting growth in advanced manufacturing

AAMM 3D printing - models of the Eiffel Tower

Cutting edge 3D metal printers are keeping South Australian advanced manufacturing in the game with the innovative technology already attracting some 100 companies to the Playford region of Adelaide.

[Read more about SA’s innovative 3D printers boosting growth in advanced manufacturing]

Intellectual Property induction course is now live!

The Adelaide Enterprise Intellectual Property (IP) induction course is designed to help you protect your ideas by giving you insight into the legal side of intellectual property. It provides an overview of intellectual property and how you can protect your ideas, as well as on aspects such as trade marks, copyright and patents.

[Read more about Intellectual Property induction course is now live!]

Carina Biotech awarded $2.1 million Federal Government CRC-P grant

Simon and Veronika from Carina Biotech

Adelaide’s Carina Biotech has been awarded a $2.1 million Cooperative Research Centre Project (CRC-P) Program grant to continue its groundbreaking work developing new cell therapies to treat solid, pediatric and rare cancers.

[Read more about Carina Biotech awarded $2.1 million Federal Government CRC-P grant]

Microbiotica collaborates with University of Adelaide to develop a novel microbial therapy for ulcerative colitis

"Cambridge, UK, 18 June 2018 – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it has entered into an agreement with University of Adelaide as part of its programme to develop a defined bacterial product for ulcerative colitis (UC). Financial details have not been disclosed.

[Read more about Microbiotica collaborates with University of Adelaide to develop a novel microbial therapy for ulcerative colitis]

RSS News Feed